DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
Apheresis Equipment Market is expected to reach USD 3.7 billion by 2024
Highlights
· The global apheresis equipment market is expected to reach USD 3.7 billion by 2024, according to a new report by Grand View Research, Inc.
· The apheresis equipment industry is expected to be impacted by factors such as rising demand for plasma, platelets and other blood components, increasing incidence of chronic illnesses, presence and development of ideal reimbursement policies across various regions, and supportive government initiatives.
· Growing incidence of blood related disorders leading to the rise in demand for platelets and plasma is expected to serve the market as a high impact rendering driver.
· Disposable apheresis kits are anticipated to dominate the product segment by 2024.
· The photopheresis procedure is anticipated to witness lucrative growth owing to its rising demand in treatment.
Related Content
-
videos & visualsNashville Doctor Performs First Successful Gene Editing Procedure on Sickle Cell Anemia Patienthttps://www.youtube.com/watch?v=s7TPRomV...
-
education & researchNutrition for the Child with Sickle Cell AnemiaSickle Cell Disease (SCD), also called S...
-
education & researchHydroxyurea (hydroxycarbamide) for sickle cell diseaseBACKGROUND: Sickle cell disease (SCD) i...
-
news & eventsFDA agrees accelerated approval pathway for GBT’s voxelotorGlobal Blood Therapeutics, Inc. ...
-
news & eventsCTX001 Earns FDA’s Fast Track Status for Treating Sickle Cell DiseaseThe U.S. Food and Drug Administration (F...
-
news & eventsA new Sickle Cell Disease Drug Holds Much Promise but Most Sufferers Won’t be Able to Afford itThe regulatory approval of a groundbreak...
-
news & eventsGBT expands sickle cell disease pipeline with worldwide licensing agreement for inclacumab for the treatment of vaso...Global Blood Therapeutics, Inc...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.